18 F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma

Hall, David O; Hooper, Clare E; Searle, Julie; Darby, Michael; White, Paul; Harvey, John E; Braybrooke, Jeremy P; Maskell, Nick A; Masani, Vidan; Lyburn, Iain D

Abstract

© 2018 Wolters Kluwer Health, Inc. All rights reserved. Purpose The purpose of this study was to compare the use of fluorine-18-fluorodeoxyglucose (18 F-FDG) PET with computed tomography (CT) and dynamic contrast-enhanced (DCE) MRI to predict prognosis and monitor treatment in malignant pleural mesothelioma. Patients and methods 18 F-FDG PET/CT and DCE-MRI studies carried out as part of the South West Area Mesothelioma Pemetrexed trial were used. 18 F-FDG PET/CT and DCE-MRI studies were carried out before treatment, and after two cycles of chemotherapy, on patients treated with pemetrexed and cisplatin. A total of 73 patients were recruited, of whom 65 had PET/CT and DCE-MRI scans. Baseline measurements from 18 F-FDG PET/CT (maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis) and DCE-MRI (integrated area under the first 90s of the curve and washout slope) were compared with overall survival (OS) using Kaplan-Meier and Cox regression analyses, and changes in imaging measurements were compared with disease progression. Results PET/CT and DCE-MRI measurements were not correlated with each other. Maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis were significantly related to OS with Cox regression analysis and Kaplan-Meir analysis, and DCE-MRI washout curve shape was significantly related to OS. DCE-MRI curve shape can be combined with 18 F-FDG PET/CT to give additional prognostic information. Changes in measurements were not related to progression-free survival. Conclusions 18 F-FDG PET/CT and DCE-MRI give prognostic information in malignant pleural mesothelioma. Neither PET/CT nor DCE-MRI is useful for monitoring disease progression.

Citation

Hall, D. O., Hooper, C. E., Searle, J., Darby, M., White, P., Harvey, J. E., …Lyburn, I. D. (2018). 18 F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma. Nuclear Medicine Communications, 39(2), 161-170. https://doi.org/10.1097/MNM.0000000000000789

• Journal Article Type: Article
• Acceptance Date: Nov 27, 2017
• Publication Date: Jan 1, 2018
• Deposit Date: Jan 19, 2018
• Publicly Available Date: Jan 24, 2018
• Journal: Nuclear Medicine Communications
• Print ISSN: 0143-3636
• Electronic ISSN: 1473-5628
• Publisher: Lippincott, Williams & Wilkins
• Peer Reviewed: Peer Reviewed
• Volume: 39
• Issue: 2
• Pages: 161-170
• DOI: https://doi.org/10.1097/MNM.0000000000000789
• Keywords: 18F-Fluorodeoxyglucose, PET/CT, dynamic, contrast-enhanced, MRI, imaging biomarkers, malignant, pleural mesothelioma
• Public URL: https://uwe-repository.worktribe.com/output/874224
• Publisher URL: https://journals.lww.com/nuclearmedicinecomm/Citation/2018/02000/18F_Fluorodeoxyglucose_PET_CT_and_dynamic.10.aspx
• Additional Information: Additional Information : This is the author's accepted manuscript. The final, published version is available at https://journals.lww.com/nuclearmedicinecomm/Citation/2018/02000/18F_Fluorodeoxyglucose_PET_CT_and_dynamic.10.aspx